Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-a2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 18; no. 10; pp. 1691 - 1697
Main Authors MIDDLETON, M, HAUSCHILD, A, THOMSON, D, ANDERSON, R, BURDETTE-RADOUX, S, GEHLSEN, K, HELLSTRAND, K, NAREDI, P
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 2007
Subjects
Antineoplastic agents
Biological and medical sciences
Dermatology
Medical sciences
Pharmacology. Drug treatments
Tumors of the skin and soft tissue. Premalignant lesions
Antineoplastic agent
Human
interleukin-2
Alpha interferon
Toxicity
Treatment efficiency
Multicenter study
Cytokine
phase III
melanoma
Histamine dihydrochloride
Malignant tumor
Dacarbazine
Alkylating agent
Randomization
Treatment
Interleukin 2
Immunotherapy
Malignant melanoma
Clinical trial
Advanced stage
clinical trials
interferon alpha
Comparative study
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041